Methods for treatment of HIV and other infections using A T cell or viral activator and anti-retroviral combination therapy

Patent Citations (14)

Non-Patent Literature (39)

• Wilson et al., “Ex Vivo Expansion of CD4 Lymphocytes from Human Immnodeficiency Virus Type-1 Infected Persons . . . ” JID 172:88-96, 1995.Applicant
• Allison, J., “Structure, function, and serology of the T-cell antigen receptor complex” Annu. Rev. Immunol. 5:503-40, 1987.Applicant
• Anderson et al., “Cross-linking of T3 (CD3) with T4 (CD4) enhances the proliferation of resting T lymphocytes” J. of Immunology 139(3):678-682, 1987.Applicant
• Bank et al., “Perturbation of the T4 molecule transmits a negative signal to T cells” J. of Exper. Med. 162(4):1117-1408, 1985.Applicant
• Bernard et al., “A novel human leukocyte differentiation antigen: monoclonal antibody anti-D44 defines . . . ” J. of Immunology 132(5):2338-2344, 1984.Applicant
• Caliendo et al., “Combination therapy for infection due to human immunodeficiency virus type 1” Clinical Infectious Diseases 18:516-24, 1994.Applicant
• D'Aquila, R., “HIV-1 drug resistance” Clinics in Laboratory Medicine 14(2):393-422, 1994.Applicant
• Emmrich et al., “Synergism in the activation of human CD8 T cells by cross-linking the T-cell receptor . . . ” Proc. Nat'l. Acad. Sci. USA 83:8298-8302, 1986.Applicant
• Finzi et al., “Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy” Science 278:1295-1300, 1997.Applicant
• Fleischer et al., “Function of the CD4 and CD8 molecules on human cytotoxic T lymphocytes: regulation . . . ” J. of Immunology 136(5):1625-1628, 1986.Applicant
• Kaye et al., “The Fab fragment of a directly activating monoclonal antibody that precipitates a disulfide-linked . . . ” J. Exp. Med. 159:1397-1412, 1984.Applicant
• Kellam et al., “Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes . . . ” Proc. Nat'l. Acad. Sci. USA 89:1934-1938, 1992.Applicant
• Kipps et al., “Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed . . . ” J. Exp. Med. 161:1-17, 1985.Applicant
• Landau et al., “The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin . . . ” Nature 334(6178):159-162, 1988.Applicant
• Larder et al., “Multiple mutations in HIV-1 reverse trasncriptase confer high-level resistance to zidovudine (AZT)” Science 246:1089-1212, 1989.Applicant
• Lazarovits et al., “Lymphocyte activation antigens” J. of Immunology 133(4):1857-1862, 1984.Applicant
• Leontsini et al., “Physical and functional associate of the T cell receptor and the T3 molecular . . . ”.Applicant
• Levy, J., “Pathogenesis of human immunodeficiency virus infection” Microbiological Reviews 57(1):183-289, 1993.Applicant
• Mason, D., “Effector mechanisms in allograft rejection” Ann. Rev. Immunol. 4:119-45, 1986.Applicant
• Milstein et al., “Hybrid hybridomas and their use in immunohistochemistry” Nature 305:537-540, 1983.Applicant
• Moretta et al., “Clonal heterogeneity in the requirement for T3,T4, and T8 molecules in human cytolytoc . . . ” J. Exp. Med. 159:921-934, 1984.Applicant
• Morimoto, et al., “The isolation and characterization of the human helper inducer T cell subset” J. of Immunology 134(6):3762-3769, 1985.Applicant
• Parham, P., “In vitro production of a hybrid monoclonal antibody that preferentially binds to cells that . . . ” Human Immunology 12:213-221, 1985.Applicant
• Perez et al., “Specific targeting of human peripheral bloot T cells by heteroaggregates containing . . . ” J. of Exp. Med. 163:166-178, 1986.Applicant
• Reinherz et al., “Subpopulations of the T4 inducer T cell subset in man: Evidence for an amplifier . . . ” J. of Immunology 126(1):67-70, 1981.Applicant
• Rosenberg et al., “The immunopathogenesis of HIV Infection” Advances in Immunology 47:377-431, 1989.Applicant
• Sattentau et al., “Epitopes of the CD4 antigen and HIV infection” Science 234(4780):1048-1123, 1986.Applicant
• Schinazi et al., “Mutations in HIV-1 reverse trasncriptase and protease associated with drug resistance” Int'l. Antiviral News 2(5):72-75, 1994.Applicant
• Shaw et al., “Susceptibility of cytotoxic T lymphocyte (CTL) clones to inhibition by anti-T3 and anti-T4 . . . ” J. of Immunology 134(5):3019-3026, 1985.Applicant
• Shearer et al., “Early T-helper cell defects in HIV infection” AIDS 5(3):245-253, 1991.Applicant
• Staerz et al., “Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity” Proc. Nat'l. Acad. Sci. USA 83:1435-1457, 1986.Applicant
• St. Clair et al., “Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse trancriptase” Science 253:1457-1612, 1991.Applicant
• Terasai et al., “Microdroplet testing for HLA-A, -B, -C and -D antigens” Amer. J. of Clinical Pathology 69:103-20, 1978.Applicant
• Van Wauwe et al., “OKT3: A monoclonal anti-human T lumphocyte antibody with potent mitogenic properties” J. of Immunology 124(5):2708-2713, 1980.Applicant
• Walker et al., “Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell . . . ” Eur. J. Immunol. 17:873-880, 1987.Applicant
• Wong et al., “Recovery of replication-competent HIV despite prolonged suppression of plasma viremia” Science 278:1291-1295, 1997.Applicant
• Wong et al., “Bi-specific monoclonal antibodies: selective binding and complement fixation to cells . . . ” J. of Immunology 139(4):1369-1374, 1987.Applicant
• Wong et al., “Bi-specific monoclonal antibodies (BSMAB): selective destruction and proliferation . . . ” Federation of Amer. Soc. for Exp. Biology, 72nd Annual Meeting, Abstract #8898, 1988.Applicant
• Wong et al., “Bi-specific monoclonal antibody (BSMA): production by fusion of pre-existing hybridomas . . . ” J. of Allergy and Clinical Immunology, 42nd Annual Meeting, Abstract #434, 1986.Applicant